Landmark Study Demonstrates Sustained Clinical Benefits of Flexitouch® Plus as First-Line Therapy in Treating Head and Neck Cancer-Related Lymphedema

Stock Information for Tactile Systems Technology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tactile Systems Technology Inc.

Tactile Medical to Present at the Piper Sandler 37th Annual Healthcare Conference
Tactile Systems Technology, Inc. Reports Third Quarter 2025 Financial Results
Tactile Medical to Release Third Quarter of Fiscal Year 2025 Financial Results on November 3, 2025
Tactile Systems Technology, Inc. Reports Second Quarter 2025 Financial Results
Tactile Medical to Release Second Quarter of Fiscal Year 2025 Financial Results on August 4, 2025
New Data Demonstrates Significant Clinical and Quality-of-Life Benefits of Flexitouch® Plus in Treating Lymphedema Among Head and Neck Cancer Survivors
Tactile Medical to Present at Upcoming Investor Conferences in June
Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.